SCIENTIFIC EVIDENCE

Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.

International journal of immunopathology and pharmacology
Meng X, Du G, Ye L, Sun S, Liu Q, Wang H, Wang W, Wu Z, Tian J.

Publication Overview

Key findings, Countstar context, and access to the original paper.
2017
Cancer Research
Immunology
No items found.
Key Finding
NLG919 can potentiate the antitumor efficacy of paclitaxel without increasing its side effects, suggesting that the combination of IDO inhibitor-based immunotherapy with chemotherapy could be a potential strategy for cancer treatment.
Countstar Connection
A Countstar instrument quantified cell numbers in the study's cell samples during growth assessment in the 2017 International journal of immunopathology and study.
View paper ↗
Stay Connected toCountstar Science
Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.
Meet us online
Products
About Us
Contact
© 2026 Countstar. All rights reserved.